Search
XOMA Royalty Corp
XOMAAdd to Watchlist
41.629USD
-0.371-0.88%
Market hours （ET）Quotes delayed by 15 min
495.80MMarket Cap
25.20P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-0.88%
5 Days
+0.82%
1 Month
+5.63%
6 Months
+27.54%
Year to Date
+56.56%
1 Year
+55.68%
TradingKey Stock Score of XOMA Royalty Corp
Currency: USD Updated: 2026-05-14Key Insights
XOMA Royalty Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 29 out of 80 in the Media & Publishing industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 44.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
XOMA Royalty Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
XOMA Royalty Corp Highlights
StrengthsRisks
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 996.03% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 52.15M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 25.42, at a high 3-year percentile range.
Held by Invesco
Star Investor Invesco holds 3.36K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.68.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
44.500
Target Price
+6.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
XOMA Royalty Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
XOMA Royalty Corp Info
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Ticker SymbolXOMA
CompanyXOMA Royalty Corp
CEOMr. Owen P. Hughes, Jr.
Websitehttps://xoma.com/
Related Instruments
+0.24%
-1.77%
-0.20%
-0.23%
-0.07%
+0.17%
-1.80%
-0.29%
+1.87%
+0.61%
-0.80%
-2.76%
-0.74%
+0.36%
-1.25%
-0.90%
0.00%
-1.06%
+0.65%
-1.16%Popular Instruments
101.390
+2.527 (+2.56%)
302.200
+3.990 (+1.34%)
227.545
-8.195 (-3.48%)
4543.760
-106.470 (-2.29%)
480.400
-8.750 (-1.79%)
1403.970
+21.250 (+1.54%)
739.620
-36.390 (-4.69%)
397.180
-3.890 (-0.97%)
79139.760
-2242.280 (-2.75%)
426.095
-17.205 (-3.88%)
